Company intelligence / Profile preview

TCG Crossover Management

Palo Alto, California, United States

Ownership: Private
Employees: ~16
Development stage: Other

Overview

TCG Crossover (TCGX) is a specialized life sciences investment firm that manages crossover funds dedicated to innovative biotechnology companies. Founded in 2020 by Dr. Chen Yu (formerly of Vivo Capital), the firm provides growth capital to both private and public companies leveraging scientific breakthroughs to develop transformative medicines. TCGX operates as an operationally independent entity within the broader ecosystem of The Column Group (TCG) and has raised over $3.1 billion across three funds as of October 2025. Its portfolio features high-profile biotech ventures in areas such as oncology, rare diseases, and immunology.

Industry: Investors

Partnerships

The Column Group

Beyond the preview

Go deeper on TCG Crossover Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCG Crossover Management.

Explore the full profile